Announcements
Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Original Research
Effect of serum progesterone level on the day of humanchorionic gonadotropin injection on outcome following in vitro fertilization-embryo transfer in women using gonadotropin releasing hormone antagonists
Show Less
1
The University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School at Camden Cooper Hospital/University Medical Center, Department of Obstetrics and Gynecology Division of Reproductive Endocrinology & Infertiliry, Camden, NJ (USA)
Clin. Exp. Obstet. Gynecol. 2011, 38(4), 322–323;
Published: 10 December 2011
Abstract
Purpose: To determine if there is any association of serum progesterone(P)level at the time of human chorionic gonadotropin (hCG)injection and pregnancy outcome in in vitro fertlization (IVF) cycles using gonadotropin releasing hormone (GnRH) antagonists forcontrolled ovarian hyperstimulation (COH). Methods: A retrospective analysis of lVF cycles over a six and a half-year period whereeither cetrorelix or ganirelix was used with COH and at least two embryos were transferred. Female partners were ≤ 35. Four differ-ent serum progesterone (P) ranges were evaluated from ≤ 0.5 ng/mL to 1.9 ng/mL; P was measured by ELISA. Results: There was nosignificant difference in pregnancy rates or even a trend in that direction with increasing serum P levels with either GnRH antagonist. Conclusions: At least with COHcycles using GinRH antagonists and where serum P is measured by ELISA there does not seem to beany disadvantage of higher serum P levels up to 2 ng/mL at the time of hCG in IVF-ET cycles.
Keywords
Progesterone
Cetrorelix
Ganirelix
Pregnancy outcome